| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Aktis Oncology, Inc.$24.89
-0.13 (-0.52%)
D 28Pipeline Score Richly Valued Pharma · Clinical
Market Cap
1.09 B
EPS
-
P/E Ratio
-
Value Trade
5.33 M
6.55 %
Week
-2.02 %
1 Month
11.64 %
3 Month
-9.4 %
6 Month
-9.4 %
5 Year
-9.4 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
260.63 K
52 Week Range
14.72 - 24.50
% held by Insiders
42.48 %
% held by Institutions
46.03 %
Enterprise Value
559.31 M
Total Shares
53.37 M
Short %
14.38 %
Float Shares
23.00 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D28
Pipeline Score $56M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 31%
Micro Cap (rank 630 of 912)
Percentile RankAktis Oncology, Inc. faces pipeline headwinds (28/100), with $193M risk-adjusted pipeline value, led by Ac-AKY-2519 in Castration Resistant Metastatic Prostate Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ac-AKY-2519 Small molecule | Castration Resistant Metastatic Prostate Cancer | Phase 1 | NCT07581184 | 5% | $177M | RECRUITING | 138 | VERY_FAST | D (20) | Jun 1, 2032 | - | LOW Jul 14, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AKY-2519 | B7-H3 expressing tumors, including metastatic castration-resistant prostate cancer (mCRPC) | Phase 1b | 2026-05-21 | robust tumor uptake; limited normal tissue exposure | Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors Read More | |
AKY-2519 | B7-H3 expressing tumors, including metastatic castration-resistant prostate cancer (mCRPC) | Phase 1b | 2026-05-21 | robust tumor uptake; limited normal tissue exposure | Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors Read More | |
AKY-2519 | B7-H3 expressing tumors, including metastatic castration-resistant prostate cancer (mCRPC) | Phase 1b | 2026-05-21 | robust tumor uptake; limited normal tissue exposure | Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AKTS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AKTS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AKTSAktis Oncology to Present at the Jefferies Global Healthcare Conference
Aktis Oncology, a clinical-stage oncology company, will present at the Jefferies Global Healthcare Conference on June 3, 2026. CEO Matthew Roden will discuss the company's innovative miniprotein radioconjugate platform, which aims to address unmet needs in cancer treatment. The event will be accessible via a live webcast, with an archived replay available for 90 days.
Read more →AKTSAktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
Aktis Oncology reported promising first-in-human clinical imaging and dosimetry data for AKY-2519, a radioconjugate targeting B7-H3 expressing tumors. The data indicated robust tumor uptake and minimal exposure to normal tissues, supporting the advancement of a broad clinical development program. Results will be presented at the 2026 ASCO Annual Meeting, with further trials expected to begin later this year.
Read more →AKTSAktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
Aktis Oncology reported its financial results for Q1 2026, highlighting the initiation of a Phase 1b clinical trial for AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC). The company also announced a second trial strategy for AKY-2519 and ongoing enrollment for AKY-1189. Financially, Aktis has a strong cash position, but it also noted an increase in net loss and R&D expenses.
Read more →AKTSAktis Oncology to Present at the BofA Securities Health Care Conference
Aktis Oncology will present at the BofA Securities Health Care Conference on May 13, 2026. CEO Matthew Roden will discuss the company's innovative miniprotein radioconjugate platform, which targets various solid tumors. Aktis aims to address unmet patient needs through its advanced pipeline, including programs targeting Nectin-4 and B7-H3.
Read more →AKTSAktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Aktis Oncology has initiated a Phase 1b clinical trial for AKY-2519, targeting metastatic castration-resistant prostate cancer (mCRPC). This trial is part of a broader strategy that includes a second basket trial for other solid tumors expressing B7-H3. Preliminary data from the mCRPC trial is expected in 2027, highlighting the company's commitment to addressing significant unmet needs in cancer treatment.
Read more →AKTSAktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Aktis Oncology announced that clinical imaging and dosimetry data for AKY-2519 will be presented at the 2026 ASCO Annual Meeting. The data will enhance understanding of AKY-2519's biodistribution in patients with B7-H3 expressing solid tumors. A Phase 1b clinical trial for AKY-2519 is set to begin in mid-2026.
Read more →AKTSAktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
Aktis Oncology has appointed Glenn Gormley, MD, PhD, to its Board of Directors and as co-chair of the Science and Technology Committee. Gormley brings extensive experience in biopharmaceutical leadership and oncology innovation, having previously led significant developments in antibody drug conjugates. His appointment coincides with the planned departure of two board members, marking a strategic shift as Aktis advances its targeted radiopharmaceuticals pipeline.
Read more →AKTS▲ +8.9%on this news
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
Aktis Oncology has received FDA clearance for its Investigational New Drug applications for AKY-2519, a miniprotein radioconjugate targeting B7-H3 in solid tumors. The company anticipates starting a Phase 1b clinical trial for AKY-2519 in mid-2026, alongside ongoing trials for its lead candidate, AKY-1189. Aktis reported a net loss of $63.7 million for 2025 but maintains a strong cash position to support its operations.
Read more →AKTSAktis Oncology to Present at Upcoming March 2026 Investor Conferences
Aktis Oncology, Inc. announced that its CEO, Matthew Roden, will present at two investor conferences in March 2026. The presentations will highlight the company's advancements in targeted radiopharmaceuticals, particularly their proprietary miniprotein radioconjugate platform. This platform aims to enhance cancer treatment efficacy while minimizing side effects. The conferences will take place in Boston and Miami.
Read more →AKTSAktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
Aktis Oncology has announced that the FDA granted Fast Track designation to its drug AKY-1189, aimed at treating adult patients with locally advanced or metastatic urothelial cancer. This designation allows for expedited development and review processes, addressing a significant unmet medical need. AKY-1189 utilizes a miniprotein radioconjugate platform to target Nectin-4 expressing tumors, with a Phase 1b clinical trial currently underway.
Read more →Competitive Position
How AKTS ranks across every disease it competes inCompetitive Position is a premium feature
See how AKTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial